FORT WORTH, TX / ACCESSWIRE / July 7, 2017 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX® Surgical Activated Collagen®, is pleased to announce the publication of the paper "Operative Closure Technique Utilizing Bovine Collagen Fragments in a Prospective Analysis of 102 Consecutive Neurosurgery Patients" by Rob Dickerman, Ashley S. Reynolds NP, and Karl Winters, in JSM Neurosurgery and Spine.
A link to the article can be found at https://www.jscimedcentral.com/Neurosurgery/neurosurgery-5-1088.pdf.
Dr. Dickerman is Clinical Associate Professor of Neurosurgery, Department of Neurosurgery, University of North Texas Health Science Center, and Director of Neurosurgery at Presbyterian Hospital of Plano, Texas. The authors present a prospective study of 102 consecutive cranial or spinal neurosurgery cases in which 1 gram of Vancomycin powder was mixed with 1 gram of Activated Collagen (CellerateRX Surgical Activated Collagen Powder) and then placed within the surgical incision. In the 102 consecutive cases, they did not have a single event of wound dehisce or infection during the 16-week follow-up. They hypothesize that the aqueous vancomycin bound to the Activated Collagen, prolonging the antimicrobial environment in the surgical site.
Please note that some of the product uses described in this publication have not been approved or cleared by FDA. Please review the prescribing information and indications for use of these products.
Payment was made by Wound Care Innovations, LLC to Dr. Dickerman's staff to cover expenses related to photography and data collection.
Wound Care Innovations, LLC is a wholly-owned subsidiary of Wound Management Technologies, Inc.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc., (the "Company") is an emerging commercial stage company with its primary products in the $5B worldwide surgical and advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product lines, CellerateRX® Activated Collagen®, which is FDA-cleared for all wound types except 3rd-degree burns. The Resorbable Orthopedic Products subsidiary owns a multi-faceted bone wax and bone void filler patent and markets products in the $1.5B biomaterials market and is anticipating new revenues from HemaQuell™ Resorbable Bone Wax. For more information visit our newly updated website, www.wmgtech.com.
Information about Forward-Looking Statements
The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE: Wound Management Technologies, Inc.